VR for Pain Management During Adult Burn Dressing Change

September 21, 2022 updated by: Henry Xiang, Nationwide Children's Hospital

Virtual Reality Distraction to Reduce Opioid Pain Medication Use During Adult Burn Dressing Change

A randomized controlled trial to evaluate the efficacy of the VR-based Pain Alleviation Tool (VR-PAT) in reducing opioid pain medication use during adult burn dressing changes.

Study Overview

Status

Completed

Conditions

Detailed Description

A pilot three group gender-balanced randomized clinical trial (RCT) among adult burn patients (18 years old or above) at OSU Medical Center Inpatient Burn Program. The intervention group will receive VR-PAT as a distraction tool during the dressing change procedure (active VR group) while the comparison groups will receive either a comparable passive VR distraction tool that uses the same hardware and visual/audio features, but requires no active interaction (Control Group 1), or no distraction at all (Control Group 2).

Study Type

Interventional

Enrollment (Actual)

14

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ohio
      • Columbus, Ohio, United States, 43205
        • Nationwide Children's Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Adult burn patient age 18-70
  2. First admission for acute burn requiring dressing change
  3. First admission for burn injury
  4. Using Opioids for dressing changes
  5. Burn is ≤ 4 days post burn

Exclusion Criteria:

  1. Severe burn(s) on the face/head preventing utilization of VR
  2. Cognitive/motor impairment preventing valid administration of study measures
  3. Unable to communicate in English
  4. Prisoners and patients who were pregnant
  5. Patients admitted to the ICU

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Active VR-PAT
Active VR-based Pain Alleviation Tool (VR-PAT) group played smart phone VR-PAT during the burn dressing changes.
Four smart phone based virtual reality games developed by the Research Information Solutions and Innovation (RISI) at the Nationwide Children's Hospital.
Experimental: Passive VR-PAT
Passive VR-based Pain Alleviation Tool (VR-PAT) group watched smart phone VR-PAT games without interaction during the burn dressing changes.
Four smart phone based virtual reality games developed by the Research Information Solutions and Innovation (RISI) at the Nationwide Children's Hospital.
No Intervention: Standard Care Control
Standard care control group used regular distraction such as background music or no distraction.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient self-reported pain
Time Frame: During burn dressing changes
Patient self-reported pain using the 100mm Visual Analog Scale (VAS), 0 (min)-100(max), higher score for worse outcome.
During burn dressing changes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Opioid medication utilization, morphine equivalent dose per day during inpatient hospital stay.
Time Frame: Each day during inpatient hospital stays up to 7 days.
Opioid pain medication use (converted to morphine equivalent dose), obtained through patient medical administration records. This data will be used as morphine equivalent dose per day, total morphine-equivalent dose during hospital stay, and average morphine-equivalent dose among active VR group, passive VR group, and standard care group in comparison.
Each day during inpatient hospital stays up to 7 days.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient VR experience
Time Frame: Subjective experience during burn dressing change, on average lasting 15-45 minutes.
Patient subjective virtual reality experience using a survey questionnaire (7 items about participant's experience with VR during burning dressing changes). Questions are a mixture of yes/no and a 100 Visual Analog Scale with 0 being "Not at All" and 100 being "Very Much"
Subjective experience during burn dressing change, on average lasting 15-45 minutes.
Nurse reported feasibility of VR in clinical burn wound care
Time Frame: Subjective observation of patient's utilization of VR during burn dressing change, on average lasting 15-45 minutes.
Attending nurse answered two questions using a survey questionnaire about clinical feasibility of VR using scale ranging from "not at all" to "very easy".
Subjective observation of patient's utilization of VR during burn dressing change, on average lasting 15-45 minutes.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Henry Xiang, MD, MPH, PhD, The Ohio State University/Nationwide Children's Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2019

Primary Completion (Actual)

November 24, 2019

Study Completion (Actual)

November 24, 2019

Study Registration Dates

First Submitted

September 1, 2020

First Submitted That Met QC Criteria

September 4, 2020

First Posted (Actual)

September 10, 2020

Study Record Updates

Last Update Posted (Actual)

September 22, 2022

Last Update Submitted That Met QC Criteria

September 21, 2022

Last Verified

September 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2018H0257

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

We are not allowed to share patient medical records data.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pain

Clinical Trials on VR-based Pain Alleviation Tool (VR-PAT)

3
Subscribe